Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
There are a number of available tests being used and often in combination, to identify more advanced liver disease.
Identifying patients most at risk of advanced liver disease is possible. Watch Dr. Tim Jobson, Gastroenterologist and Chief Investigator at Somerset Liver Improvement Project in the UK and Dr. Mark Swain, Hepatologist from the University of Calgary, as they discuss leading edge work already being done to proactively find patients most at risk.
Innovation in healthcare can change lives.
Most of us have heard about the Fibroscan as a non-invasive way to assess fatty liver disease severity and the presence of fibrosis. Today, we had a webchat with Louise Campbell, Founder and Clinical Director of Tawazun Health, who gives us the benefit of her 30 years of experience in this field in "Fibroscan 101".
Join Michael Betel and Louise Campbell, Founder and Clinical Director of Tawazun Health in this informative discussion. What do the scores mean? What is liver stiffness? Why does that matter? With what score would you refer?
- Confession Time -
After years of asking others to be assessed for fatty liver disease, I decided, since I myself have several risk factors, I should 'walk the walk' and get tested.
I approached Dr. Hsiao-Ming Jung who is a Primary Care Physician with a special designated class in Gastroenterology, and Hepatology in Family Medicine, and Owen Parr, who is a VP at Fibronostics and they have a diagnostic liver assessment called LIVERFASt.
I had blood drawn to assess 10 biomarkers, I submitted other personal info like my weight and height and waist circumference. I had an ultrasound and I actually have a Fibroscan appt today.
I want people to know that there should be no stigma attached to being evaluated for fatty liver disease. We should not be afraid to look into our health, or the health of our families.
Watch the two part video series here where I am assessed 'on-air' and learn what I should expect, (pre-test), and then in part 2, the findings!
I hope that if others at risk (who have elevated cholesterol, high BMI/obesity, type 2 diabetes, sleep-apnea etc.), get tested, they may be early enough to reverse their liver disease.
After years of asking others to be assessed for fatty liver disease, I decided, since I myself have several risk factors, I should 'walk the walk' and get tested.
I approached Dr. Hsiao-Ming Jung who is a Primary Care Physician with a special designated class in Gastroenterology, and Hepatology in Family Medicine, and Owen Parr, who is a VP at Fibronostics and they have a diagnostic liver assessment called LIVERFASt.
I had blood drawn to assess 10 biomarkers, I submitted other personal info like my weight and height and waist circumference. I had an ultrasound and I actually have a Fibroscan appt today.
I want people to know that there should be no stigma attached to being evaluated for fatty liver disease. We should not be afraid to look into our health, or the health of our families.
Watch the two part video series here where I am assessed 'on-air' and learn what I should expect, (pre-test), and then in part 2, the findings!
I hope that if others at risk (who have elevated cholesterol, high BMI/obesity, type 2 diabetes, sleep-apnea etc.), get tested, they may be early enough to reverse their liver disease.
Dr. Manal Abdelmalek, Hepatologist, Professor of Medicine at Duke University shares her expert opinion about what patients should ask their Primary Care Physician to ensure that their liver disease risks are assessed and that they are referred to a specialist for a more detailed evaluation if warranted.
Dr. Manal Abdelmalek, Hepatologist, Professor of Medicine at Duke University shares her concerns about the challenge of reaching 10M people about fatty liver disease, and the education required to ensure that those needing to seek assessment and treatment by a specialist, receive what they need.
Of the 363 million adults in North America, about 91 million may have fatty liver disease and not know it. How will we screen for that? Should we screen for that? Who is most at risk? All critical questions that need to be addressed.
Dr. Robert Gish discusses current screening options and benefits.
Dr. Manal Abdelmalek, Hepatologist, Professor of Medicine at Duke University shares her recommendations for what would be needed before screening the very high number of fatty liver patients at the Primary Care Physician level.
Dr. Manal Abdelmalek, Hepatologist, Professor of Medicine at Duke University discusses the multiple risk factors of more advanced fatty liver disease. For those with multiple risk factors, as shared in this video, the advice is to speak with your Primary Care Physician so that you could be assessed.
Nurse Practitioner, Cheryl Dale shows how easy a Fibroscan can be for patients and that there is nothing to be afraid of.
Dr. Mark Swain explains what your Physician uses to diagnose NASH. There are specific markers that are considered.
Dr. Supriya Joshi clearly explains how nonalcoholic fatty liver disease (NAFLD ) and nonalcoholic steatohepatitis (NASH) are different.
Make sure to watch this informative discussion about non-invasive liver tests (NITs). Two experts in liver NITs will share their experience and knowledge about the latest trends and advancements. Thank you Dr. Imtiaz Alam and Dr. Mona Munteanu for some really insightful sessions with Michael Betel. Learn about the differences between NITs and more about the future of liver biopsies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.